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OPINION LETTER
The current letter has been driven by the clinical observation of the events that happened in the last
months during the coronavirus disease 2019 (COVID-19) pandemic in the European countries,
with specific reference to the situation of patients in the North of Italy and in Germany.
“Specialists are people who always repeat the same mistake.”—Walter Gropius, German architect and
founder of the Bauhaus School
A 71-year-old male, Caucasian, is affected by chronic heart failure (CHF) New York Heart
Association (NYHA) class III and chronic kidney disease stage III. The first diagnosis of CHF
has been performed 4 years ago after hospitalization for acute coronary syndrome resulting in a
percutaneous coronary intervention with primary stenting. Since then, he has been hospitalized
at an average of 1.5 times per year. Two thirds of the patient’s hospitalizations were caused by
worsening of his chronic body fluid congestion with peripheral edema and impaired renal function,
while for one third of the cases, the main cause was volume depletion. This has been manifesting
with hypotension and hypokalemia as a result of challenges in managing the correct intake of
diuretics and blood pressure-lowering medications.
When admitted to the cardiology ward, such a paradigmatic patient represents a challenge,
especially with regard to the body fluid management. This requires a specialized heart failure
(HF) team with extensive experience in the field. The clinical approach to such complex patients
includes daily physical exam and control of body fluid balance through fluid intake and urine
output. On top of this, biomarkers, chest X-ray, lung ultrasound, and, for cardiorenal patients,
bioimpedance analysis are performed during the hospitalization to assess the patients’ congestion
status. Moreover, it requires a fine tuning of medications, diet, and liquid restrictions to achieve a
proper balance between body volume and blood pressure.
After recompensation and discharge, the patient is left alone with a single method to monitor
himself: a standard weight scale. He weighs himself every day, trying to keep contact with his
physician on the phone. He relies on elective appointments in the outpatient clinic, three times
a year.
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It is February 2020, and the COVID-19 pandemic takes hold.
The patient is not able to get a prompt appointment with his
physician. In case of worsening of his clinical condition, he is
being told to call the emergency number.
This situation could evolve into three different scenarios:
- No Hospitalization Needed and no SARS-CoV-19 Infection
During the Pandemic
The patient independently manages his chronic fluid congestion
based on the experience of the past years. He can avoid any
contact with COVID-19+ patients. However, the lack of a proper
medical assistance may increase the risk of experiencing a sudden
decompensation event. Compared to the time pre-COVID-19
pandemic, his mortality risk may look the same in the short
term, but it will probably drastically increase in the medium to
long term.
- Clinical Deterioration of the Patient Condition
The patient constantly deteriorates, gains weight, and his quality
of life is strongly affected. He does not get an appointment
with his general practitioner, neither in the outpatient clinics.
He manages to survive without an emergency hospitalization,
but in a poor condition, for a few weeks or months
until the pandemic situation has improved, and he receives
medical attention.
- Hospitalization for Acute Decompensation
The patient gets admitted to the hospital because of an acute
exacerbation of his condition. The hospitals are under great
pressure because of the pandemic, and the intensive care units
have limited capacity. His mortality risk may still be higher than
before the pandemic.
- Hospitalization for COVID-19
The patient is infected with SARS-CoV-19, his condition quickly
worsens, and he needs to be quickly hospitalized. The mortality
risk in this scenario is possibly the highest.
The last two scenarios are unfortunate and, most importantly,
avoidable. However, a drastic change in the management of
chronic patients is today, more than ever, of paramount
importance. In addition to the direct impact on public health,
COVID-19 has been challenging the way of living, the habits, as
well as many long-existing cultural and social structures on which
societies are based. Maybe for the first time in modern medicine,
the major strategy of healthcare policymakers has been to keep
patients outside hospitals to avoid the spread of the infection.
However, this is not enough, and remote monitoring strategies
are necessary for the future of a sustainable healthcare system (1)
for many reasons.
We are experiencing since many years a clear mismatch
between specialized physicians and patients in need of care
(2, 3). Aging in western countries has led to an increase in the
number of patients with multiple comorbidities (4). Since the
very first beginning of medicine and then throughout modern
times, healthcare systems have been structured on a face-to-
face patient–physician interaction. This kind of approach has
contributed to a hospital influx of patients during the COVID-
19 outbreak.
Several European healthcare systems seemed unprepared to
fight the pandemic, while many hospitals even contributed to
the initial spread of COVID-19. In this scenario, most of the
scheduled medical and surgical procedures were rescheduled,
while many chronic patients have been temporarily lost
at follow-up.
For these reasons, telemedicine has turned from being a “nice
to have” approach to an essential requirement (5) for a more
efficient system. Chronic HF patients are facing an increased
challenge regarding the management of body fluids.
While during a hospitalization, the volume status of the
patient is generally addressed by the medical doctors with various
methods and solutions such as physical examination, ultrasound,
chest X-ray, or blood examinations, at home, the solutions
available and specific for the prevention of decompensation
events in such patients are relatively limited, as described in
Figure 1. We now believe that a natural shift toward home
monitoring solutions should be considered and encouraged to
manage the patients’ body volume during and after the pandemic.
While invasive solutions such as cardioMEMS have already
demonstrated to decrease HF patients’ hospitalization (6), their
utilization has been limited mainly due to invasiveness and
related adverse events (7) or lack of penetrance among medical
doctors (8). The spectrum of non-invasive telemedicine is,
instead, broad, and the recent positive results achieved by Köhler
et al. (9) and confirmed by the meta-analysis of Zhu et al. (10)
are encouraging.
Audio–video tools able to connect patients and physicians
for real-time consultations are widely available and, even if still
not extensively adopted, during the pandemic, and the relative
lockdown, virtual visits (VVs) represented the first tangible
action in favor of a home monitoring of chronic patients,
obtaining positive results (11). A recent work published by
Salzano et al. (12) was able to show in a cohort of 103 HF patients
how a 24/7 audio and video management during the pandemic
is able to decrease hospitalizations and mortality compared to a
previously observed comparable population in which telemedical
support was not present or available. While the feasibility and
utility of such solutions for HF patients have been shown to
be beneficial even before the pandemic (13), a lot of work is
necessary to support a routine utilization. Even if advancements
were made in terms of reimbursements, audio/video tools are
not yet part of an organized widespread telemonitoring plan
in all countries (11). Moreover, VVs require an important
engagement by the medical doctors that many times does not
match with the time available. Centralized hospitals dedicated
only to telemedicine may solve such a problem. The Center for
Cardiovascular Telemedicine in Charité Berlin is an example of
how a centralized management of telemedicine information is
able to act successfully on distant and rural territories (9).
Portable or wearable devices collecting vital parameters while
involving the use of Web apps or smartphones are increasingly
reliable, and they represent the next generation of solutions
available for CHF patients (14). However, even if most research
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FIGURE 1 | Body fluid management in chronic heart failure and cardiorenal patients after the coronavirus disease 2019 (COVID-19) pandemic. The complex workflow
for the diagnosis and monitoring of body fluids of chronic heart failure and cardiorenal patients inside the hospitals (Left) has been restricted by the COVID-19
pandemic, causing a potentially relevant shift toward home monitoring protocols (Right).
has shown the cost-effectiveness of such devices, regulatory
authorities have slowed a full penetration of wearables in the
medical market until further clinical evidence is available (15).
Another important aspect is technological, since the correct
technology should match with the correct clinical indication. For
example, for HF patients, a further step should be taken to move
beyond the utilization of weight scales, known since many years
to be poorly accurate in detecting body fluid congestion and
body volume imbalances (14). While remote monitoring through
implantable cardioverter defibrillators (ICDs) works really well
for the detection of arrhythmias, the same cannot be said for
the management of body fluids through intrathoracic impedance
mainly due to the high risk of false positives that slowed the initial
enthusiasm (16). Even if a lot of research is undergoing in new
non-invasive technologies for the assessment of body fluids, their
clinical value still needs to be demonstrated (14).
The complex clinical scenario offered by the COVID-19
pandemic should finally be the springboard for telemedicine.
Telemedicine still presents challenges, such as the identification
of the correct patients’ populations in need, a variable that should
always be addressed first. This has been nicely demonstrated in
a recent randomized, multicenter, open-label telemedicine study
by Galinier et al. (17), where patients at higher risk and the
ones more socially isolated presented better clinical outcomes
than more stable patients, showing how telemedicine may be
more useful in such patients. Usability of technologies and
increased adherence to the monitoring plan are some of the
topics that need to be addressed to finally make telemedicine
affordable and efficient for the post-pandemic healthcare system.
On top of that, we believe that optimization of the healthcare
organization and automatization of the management processes,
meaning data collection, data interpretation, and clinical action
toward the patients, need to proceed in a highly structured and
fast path to be completely effective. This could be potentially
achieved by departments or hospitals dedicated to telemedicine
in conjunction with general practitioners. We believe that the
introduction of working telemedicine programs needs to enter
a novel stage, assigning specific duties and responsibilities to
trained personnel. A collaboration between general practitioners
and specialized centers is necessary mainly for medically
underserved and rural areas. However, the roles need to be
precisely defined to avoid confusion.
Both the Heart Failure Society of America and European
Society of Cardiology strongly encourage the use of telemedicine
for HF management during the COVID-19 outbreak (18).
However, a functioning widespread system that allows the
reimbursement of home monitoring solutions is still lacking
(19). Germany is moving in an innovative direction with the
so-called Digital Care Act, entitling all individuals covered
by statutory health insurance to reimbursement for certain
digital health applications (20). The chance of having a digital
solution reimbursed encourages the hospitals to adopt novel
telemedical solutions and produce proactively a much faster
tangible outcome.
In Italy, during the COVID-19 outbreak, several patients
experienced a poor outcome because they did not access to
health system (21). Telemedicine owns nowadays the potential
of delivering a better healthcare by empowering patients and
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by providing individualized healthcare, especially during a
pandemic (22).
Yes, it is time for telemedicine. But, first, let us make
telemedicine a matter of routine. Let us learn from our mistakes.
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